About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, June 11th, 2013

The QualityStocks
Daily Stock List



PennyStocks24 reported recently on GRILLiT, Inc. (GRLT), and today we are highlighting the Company as "One to Watch" this week here at the QualityStocks Daily Newsletter.

GRILLiT, Inc. was founded on the concept of delivering a fast-casual dining experience with fresh, nutritious home-style cooking. Leveraging more than four decades of experience in the food industry, the founders of GRILLiT established this unique business model to satisfy the ever-increasing demand for delicious and healthy food while providing the perfect ambiance for guest to relax and enjoy great cuisine.

The company sources its ingredients from local and domestic farmers to ensure crisp, fresh produce and grain-fed Angus beef. The cooking techniques and low-sodium recipes employed result in uniquely healthy and delectable meal choices. Using the best possible ingredients, GRILLiT chefs have created an inspiring flavor profile using fresh herbs spices and all-natural marinades.

The management team executing GRILLiT’s business strategy has been carefully assembled to achieve rapid growth and profitability. One of the most recent additions, Rob Elliott, brings more than 25 years of experience in restaurant franchise system development, marketing, branding, and operations. Previously serving as Vice President of Marketing for Little Caesars Pizza, he was instrumental in expanding the number of store locations from 150 to 5,000.

GRILLiT is focused on expanding throughout the southeastern United States and offers nationwide franchising opportunities. Current locations operate in high-traffic shopping plazas and offer American, Asian Fusion, and Latin American food styles. The company’s growth strategy is based on a five-year plan to roll out a total of 79 stores in nine states: Florida, Kentucky, Ohio, New Jersey, New Hampshire, North Carolina, Tennessee, Georgia, and Pennsylvania.

“As part of our growth strategy, we have recognized that much of the appeal of our brand recognition is that the majority of our food menu choices are attractive to health-conscious consumers,” GRILLiT CEO Raymond Dias stated in a recent press release. “Therefore, we are committed to making this a focal point of our upcoming marketing efforts. We are in the process of filling out our senior management, and plan to bring industry leaders in to key positions – including those with significant fast casual restaurant marketing experience.”

We're tracking GRILLiT, Inc. (GRLT) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

GRILLiT, Inc. (GRLT), closed Tuesday's trading session at $1.00, down 7.83%, on 172 volume. The stock's 52-week low/high is $0.11/$1.50.

Blast Applications, Inc. (BLAP)

Bird Gang Stocks, HotStockChat, Bull in Advantage, OTC Picks, and Steaming Red Hot Picks reported previously on Blast Applications, Inc. (BLAP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 2002, Blast Applications, Inc. is a premier creator and developer of applications for iPhone, iPad, Facebook, and Android that makes spending time on these sites easier, more productive and more intuitive. The Company previously went by the name Medivisor, Inc. They changed their name to Blast Applications, Inc. in July of 2009. The Company lists on the OTC Pink Current Information. Blast Applications has their corporate headquarters in Plainview, New York.

The CEO/President of Blast Applications is Mr. Dino Luzzi. In 1999, he worked with Glenn Michael Financial in assisting in raising capital for Keytrade Online, an online brokerage firm that was acquired by a Latin American financial portal, Patagon.com International. In 2002, Mr. Luzzi became CEO of Medivisor. In 2009, he was appointed CEO of Blast Applications.

Currently, the Company owns and operates Tweact.com, Twuition.com, Tweexchange.com, Twedemption.com, CanDoBetter.com, Blastapplications.com, and Taskslive.com. Blast Applications designs, develops, optimizes, and implements mobile solutions for companies who desire to engage their customers' by way of the mobile market.

Blast Applications offers an assortment of applications. These include TasksLive for workgroup task management; CanDoBetter, a matching portal, and Twedemption that allows one to clean up their Twitter box. Applications also include Twuition, which enables customers to use Twitter; Tweexchange for Twitter and domain name search; as well as Tweact, an application that enables users to flip their text and paste it across the social Web.

In January of this year, Blast Applications reported that they entered a revenue share agreement with MBS Value, LLC. An Independent Sales Organization, MBS is contracted with Charge Card Systems, affiliated with First Data, a Fortune 50 company that handles merchant processing for close to 70 percent of the credit card transactions in the country. Blast Applications selected MBS because of their first-rate servicing and many endorsements by Associations representing small business owners across America.

Blast Applications, Inc. (BLAP), closed at $0.0193, up 22.15%, on 3,243,423 volume with 82 trades. The average volume for the last 60 days is 656,225 and the stock's 52-week low/high is $0.0002/$0.0158.

PetroFrontier Corp. (PFC.V)

Today we are reporting on PetroFrontier Corp. (PFC.V), here at the QualityStocks Daily Newsletter.

PetroFrontier Corp. is an international oil and gas exploration company whose shares trade on the TSX Venture Exchange and the OTC Pink Current Information (PFRRF). On January 14, 2011, PetroFrontier became a publicly traded company listed on the Toronto Stock Exchange (TSX) Venture Exchange (PFC.V) because of the amalgamation of Pendulum Capital Corp., a capital pool company and Australia Energy Corp. (AEC). PetroFrontier has their headquarters in Calgary, Alberta, and an operations office in Adelaide, South Australia.

Founded in 2009, PetroFrontier is one of the first companies to explore in the Southern Georgina Basin in Australia's Northern Territory. The Company engages in the exploration, acquisition and development of conventional and unconventional petroleum assets in the Southern Georgina Basin where, before the Amended Farmin Agreement, the Company held an approximate 85.5 percent working interest in 14.1 million gross acres.

The Ryder Scott Resource Report (November 2010 – an independent report), estimated recoverable oil resources of 27.5 billion barrels (P50, gross average) on PetroFrontier's lands. The belief is that most of the Company's lands are in the apparent oil mature window of hydrocarbon potential, in particular, conventional oil targets and the unconventional Lower Arthur Creek Formation.

Today, PetroFrontier announced that they agreed to amend the existing farmin agreement with Statoil Australia Oil & Gas AS. Statoil has committed to spend the next US$50 million throughout the remainder of 2013 and 2014 to fully fund up to a 385 km 2D seismic program and the drilling and stimulation of four to six vertical test wells (the Amended Farmin Agreement).

Under the Amended Farmin Agreement, Statoil could spend up to US$175 million by the end of 2016 before PetroFrontier will be required to contribute further. Statoil will also become the operator effective September 1, 2013.

Under the terms of the Amended Farmin Agreement, up to the next US$160 million of exploration costs will be fully funded by Statoil over three phases to the end of 2016. This is in return for 80 percent of PetroFrontier's working interest (WI) in EP 103/EP 104 (100 percent WI), EP 127/EP 128 (75 percent WI) and EPA 213/EPA 252 (100 percent WI) in the Southern Georgina Basin. Statoil is a global technology-oriented energy company focusing on upstream oil and gas operations.

PetroFrontier Corp. (PFC.V), closed Tuesday's trading session at $0.245, up 48.48%, on 2,724,699 volume. The stock's 52-week low/high is $0.09/$1.17.

Stratex Oil & Gas Holdings, Inc. (STTX)

Wall Street Resources reported this week on Stratex Oil & Gas Holdings, Inc. (STTX), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Stratex Oil & Gas Holdings, Inc. concentrates on the exploration, acquisition, and production of crude oil in the Bakken and Three Forks formations in North Dakota and Montana. An independent energy company, their corporate strategy is to internally identify prospects, acquire lands including those prospects, and evaluate those prospects using subsurface geology, geophysical data, and exploratory drilling. Stratex lists on the OTC Markets' OTCQB.

The Company works to retain operations on their lands wherever possible to control the timing of the development of their leaseholds. Stratex currently owns an interest in 166 oil wells that is the source of their revenue. The Company recently reported that revenues generated from oil production for the period ended March 31, 2013 were approximately $267,000 in comparison to $220,000 in the same period a year prior. The 21 percent increase was due to the increase in the number of and interest in producing wells owned by Stratex Oil & Gas in the relevant periods.

Stratex Oil & Gas' oil and natural gas operations are principally concentrated in two Rocky Mountain basins. These are the Williston Basin of North Dakota and Montana, and the Denver-Julesberg Basin of Colorado, Nebraska, and Kansas. In the Williston Basin, Stratex focuses on oil production from multiple zones including the Bakken Shale and Three Forks Sanish Formations. In the Denver-Julesberg Basin, the Company focuses on the Niobrara Formations. Moreover, Stratex owns an operating interest in a producing well in Roosevelt County, Montana.

In May, Stratex Oil & Gas announced that the Company is converting the Minzenmayer 3 well to a salt water disposal well to aid in the daily production volume of the Minzenmayer 3-B well. Since reopening the Minzenmayer 3-B in March 2013, the well has been limited in its daily oil production because of the lack of salt water disposal capabilities on site. Stratex believes the conversion of the Minzenmayer 3 will more than double the production of the Minzenmayer 3B. They will continue to evaluate the Runnels County prospect for additional daily production.

Stratex Oil & Gas Holdings, Inc. (STTX), closed Tuesday's session at $1.29, up 5.74%, on 373,552 volume with 180 trades. The average volume for the last 60 days is 118,970 and the stock's 52-week low/high is $0.75/$2.90.

Envivio, Inc. (ENVI)

Stock Stars, MonsterStocksPick, The Street, Street Insider, Stockpalooza, and AheadoftheBulls.co reported earlier on Envivio, Inc. (ENVI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Envivio, Inc. is a leader in solutions for multi-screen video processing and delivery. The Company's goal is to make the world's video content universally enjoyable by all viewers, on any device, across any network, at any time. Envivio launched in 2000 as an inventor of video encoding technology. The Company has their headquarters in South San Francisco, California and has offices globally, including France, England, China, Singapore and Japan.

Since their inception, Envivio has accumulated dozens of patents, pioneered video-over-IP methods, and continually leads with support for emerging technology. This includes the first H.264 encoder and the first encoder to support multiple devices and networks simultaneously, to the first solution for protecting and delivering premium TV services to the iPhone.

Envivio uses their encoding technology as a foundation. They provide complete solutions that leverage modern networks to deliver live and on demand video services to consumers. Their software-based solutions provide operators the flexibility to upgrade and easily scale their systems to improve video quality, add functionalities, as well as support new devices. Their solutions include Ad Insertion, IPTV, Live Processing, Statistical Multiplexing, Switched Digital Video, TV Everywhere, and Video On-Demand.

The Company's products include Envivio Muse™ encoders. These provide a high quality, all-digital live or file-based workflow that fits new and existing environments, simplifies operations, reduces equipment requirements and controls expansion costs. Their Envivio Halo™ encrypts, packages, stores and distributes video streams for TV Everywhere and TV Anytime services.

At the end of May, Envivio announced financial results for the first quarter of fiscal 2014 ended April 30, 2013. Revenue for the first quarter of fiscal 2014 was $7.5 million, versus $7.7 million in the fourth quarter of fiscal 2013 and $13.4 million in the first quarter of fiscal 2013. GAAP net loss for the quarter was $4.7 million, or $0.18 per share. This is in comparison to a GAAP net loss of $4.9 million, or $0.18 per share, in the fourth quarter of fiscal 2013 and a GAAP net loss of $2.2 million, or $0.17 per share, in the first quarter of fiscal 2013.

Envivio, Inc. (ENVI), closed Tuesday's trading session at $1.90, up 8.57%, on 712,576 volume with 2,142 trades. The average volume for the last 60 days is 93,798 and the stock's 52-week low/high is $1.42/$8.15.

Trevali Mining Corp. (TV.TO)

Stockhouse reported previously on Trevali Mining Corp. (TV.TO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

With active operations in Canada and Peru, Trevali Mining Corp. is a zinc-focused base metals development enterprise. Listed on the Toronto Stock Exchange, the Company's strategy includes achieving Mid-Tier Mining Company status via a combination of organic growth and innovative deals and strategic alliances. Their corporate strategy also includes focusing exploration activities in highly prospective, under-explored terrain in countries and regions that offer security of tenure and support mineral deposit development. Trevali Mining is based in Vancouver, British Columbia.

In Canada, the Company owns the Caribou mine and mill, the Halfmile mine, and the Stratmat polymetallic deposit all within the Bathurst Mining Camp of northern New Brunswick. Initial trial production from the Halfmile underground mine was successfully undertaken in 2012. Trevali anticipates beginning operations at their 3,000-tonne-per-day Caribou Mill Complex in early 2014.

In Peru, Trevali has started commissioning at their Santander zinc-lead-silver mine. At Santander, the Company is planning 2,000-tonnes-per-day production for this year. The 4,455-hectare (44 km2) property contains many outcropping polymetallic mineralized bodies (Magistral North, Central, South and Puajanca South). The Property is on the western edge of the Altiplano, which forms the Western Cordillera of the Andes, in the Central Peruvian Polymetallic Belt. The Santander Mine features ease of accessibility and modern infrastructure. This includes the aforementioned 2,000-tonne-per-day (tpd) processing/concentrate plant.

Moreover, through their wholly owned subsidiary, Trevali Renewable Energy, Inc., the Company plans to undertake a major upgrade of their wholly owned Tingo run-of-river hydroelectric generating facility. This is to allow, in addition to supplying power to the Santander mining operation, the potential sale of surplus power into the Peruvian National Energy Grid.

Yesterday, Trevali Mining announced that crushing of mill feed began at their Santander Mine zinc-lead-silver operations. The main crusher is now operational. Trevali has started initial processing of the mill feed at Santander that had undergone stockpiling during the ongoing underground development activities. Operations have begun filling the Fine Mill Feed Bin. The anticipation is that initial zinc and lead-silver concentrate production will start later this month with the first shipments expected next month.

Trevali Mining Corp. (TV.TO), closed Tuesday's trading session at $0.59, down 6.35%, on 448,359 volume. The stock's 52-week low/high is $0.58/$1.32.

Wave Systems Corp. (WAVX)

FeedBlitz, Stock Stars, and MonsterStocksPicks reported earlier on Wave Systems Corp. (WAVX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 1988, Wave Systems Corp. (based in Lee, Massachusetts) develops, produces, and markets products for hardware-based digital security. The basis of the Company's products is on the Trusted Platform Module (TPM). TPM is a hardware security chip that enables secure protection of files and other digital secrets, and performs critical security functions. The Company reduces the complexity, cost and uncertainty of data protection by starting inside the device.

Wave Systems takes advantage of the security capabilities built directly into endpoint computing platforms themselves - part of the hardware - not added on. Their products for the Enterprise include EMBASSY® Remote Administration Server for Self-encrypting Drives, EMBASSY® Remote Administration Server for Device Identification and Wave for BitLocker® Management, among other product offerings.

Their Legacy Products include EMBASSY® Trust Suite, EMBASSY® Trusted Drive Manager, Key Transfer Manager, Private Information Manager, TCG-Enabled Crypto Service Provider, and TCG-Enabled Toolkit. For the Client PC they have their EMBASSY Security Center product. The Company's products also include Wave Cloud and Safend Protector for Mac. Their Social Media product is scrambls; scrambles is a simple web browser plug-in that lets a person decide exactly who sees what they post to the web, including to social networking sites.  Their Electronic Records product is eSignSystems.

The Company offers solutions concerning Compliance, Data Protection, Malware Protection, and Access/Authentication. Wave Systems sells their products to chip original equipment manufacturers (OEMs), PC OEMs, enterprise customers, and systems integrators.

Recently, Wave Systems announced that they secured a Gold Server Platform competency in the Microsoft Partner Network. This demonstrates the Company's ability to meet Microsoft customers' evolving needs in today's business environment. Wave's line of software strengthens network security while eliminating the requirement for user passwords. Their solution offers seamless security, and minimizes the risk of credential theft and network hacks without the need for costly second factor authentication. In addition, their solution makes use of Microsoft native security features, including DirectAccess, Virtual Smartcard and BitLocker.

Yesterday, Wave Systems announced that they commenced an executive search for a Chief Operating Officer (COO). The COO role would be a new position at Wave Systems, responsible for day-to-day operations, developing sales channels, overhead management, execution of product and cloud services strategy, as well as other corporate goals.

Wave Systems Corp. (WAVX), closed Tuesday's trading session at $0.4379, down 4.76%, on 666,073 volume with 494 trades. The average volume for the last 60 days is 355,696 and the stock's 52-week low/high is $0.37/$1.20.

Ghana Gold Corp. (GGCO)

PennyStocks24, Epic Stock Picks, and EpicVIP Group reported this week on Ghana Gold Corp. (GGCO), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTC Pink Current Information, Ghana Gold Corp. is a gold exploration and alluvial gold production company with properties in the Republic of Ghana. The Company has strategic land positions on the world-famous Ashanti Gold Belt. Their projects range from alluvial production to exploration of hard rock concessions. The Company is looking to expand their operations to other neighboring African countries that have promising gold mining opportunities.

Ghana Gold's Jukwa Concession is their first venture in Ghana. This widespread concession is in the Western Region on the western fringe of the Ashanti Gold Belt. Production yields have surpassed forecasts. Test results and production forecasts in a more favorable location at the northern tip of the concession have the Company's future projections exceeding current ratios. 

The Company's newest venture is Grumesa on the Ofin River. It is close to the village of Grumesa in the Ashanti Region. It is directly on the shores of the Ofin River. Infrastructure has been constructed and this project is very near to the world famous Anglo Gold Ashanti mine in Obuasi, Ghana.

Additionally, Ghana Gold's projects include the Offinso Gold Fields at Ahenkro. The project is 45 km northwest of Kumasi, Ghana's second largest city. The Ahenkro site is at the northern end of the Ashanti Gold Belt. The Ahenkro is 102.05 square kilometers. The Company also has their Brofoyedro project at the River Pra. The Brofoyedro is mid-way between Ghana's largest cities of Kumasi and the capital of Accra. Ghana Gold has options for up to 80 Small Scale Concessions with a land mass approaching 2,000 acres.

Last week, Ghana Gold announced plans to change their name to Brightrock African Mining Corp.  They acquired the domain address www.brightrockafricanminingcorp.com; they are in the process of creating an updated website to facilitate disseminating updated information on their Company.

Ghana Gold has expanded operations considerably with the acquisition of Mining Concession in the Central African Republic.  The new "Bright Rock" name is part of a wide-ranging program to grow the Company and to help shareholders and the public understand that Company operations are no longer only Ghana based.

Furthermore, last week, Ghana Gold announced the appointment of Mr. Chris Ellom as Head of Operations in Ghana. Mr. Ellom is a native of Ghana and a Canadian Citizen. He received his education in England and in Canada with a background as an Engineering Technologist. He will be in charge of all Ghana Gold operations, overseeing the alluvial production and coordinating the Company's hard rock test drilling program, day-to-day operations and staffing.

Ghana Gold Corp. (GGCO), closed Tuesday's trading at $0.037, up 12.12%, on 150,776 volume with 26 trades. The average volume for the last 60 days is 466,290 and the stock's 52-week low/high is $0.015/$10.00.


The QualityStocks
Company Corner


International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.245, up 2.08%, on 26,905 volume with 12 trades. The stock’s average daily volume over the past 60 days is 116,433, and its 52-week low/high is $0.161/$0.45.

International Stem Cell Corp. announced today that their biotech subsidiary, Lifeline Skin Care, inked major distribution agreements to sell its revolutionary stem cell skin care products in the lucrative Thailand and Viet Nam markets with launches coming this summer. This move dovetails exceptionally well with the company's recently announced distribution relationship with China, marking a pivotal era in the history of ISCO's technology commercialization as they plant solid footholds in the massive Pan-Asian markets were receptivity to this technology, especially for skin care and cosmetics, is at an all-time high.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Subsidiary Lifeline Skin Care Expands Asian Distribution

International Stem Cell Corporation Initiates IND-Enabling Study in Parkinson's Disease Program

International Stem Cell Corporation to Present at Two Upcoming Investor Conferences

The Aristocrat Group Corp. (ASCC)

The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $0.28, off by 6.67%, on 564,443 volume with 71 trades. The stock’s average daily volume over the past 60 days is 295,580, and its 52-week low/high is $0.21/$1.25.

The Aristocrat Group Corp. reported today that, in order to maximize impact in the booming $21.3B domestic spirits market, which will be led by their debut of RWB Ultra-Premium Handcrafted Vodka, an all-American spirit with federal approval to advertise its gluten-free status right on the label, the company has moved to handle distribution in-house. ASCC will be moving its brands through its own wholly-owned subsidiary, TOP Shelf Distributing, in a strategic decision planned to give the company's products optimal success rate in key target markets, as well as the broader space.

The Aristocrat Group Corp. (ASCC) is a brand management company focused on providing premiere luxury goods through continual innovation. Luxuria Brands, a subsidiary of The Aristocrat Group, has been established to identify and promote unique brands that have mass market appeal across a diverse demographic.

Luxuria Brands is primarily concentrated on distilled spirits industries, with an initial focus on Vodka branding and marketing. The worldwide distilled spirits market is currently worth about $263 billion. In the U.S. alone, Vodka sales between 2004 and 2009 grew 25% from 13.9 million cases to 58.4 million cases. The clear liquor now accounts for almost a third of all distilled spirits consumed and continues to rise in popularity.

The Aristocrat Group is also pursuing opportunities in the women’s lifestyle industry. The World Bank recently estimated that the earning power of women will reach $18 trillion by 2014, which is twice the estimated 2014 GDP of China and India combined. The Aristocrat Group is working to bring fresh, innovative prenatal and postpartum solutions to women who are looking for a more comprehensive approach to wellness.

The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. The company aims to take a leadership position in multiple growing markets that offer opportunities for partnership, sponsorship, and brand awareness activities. The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. Disclaimer

The Aristocrat Group Corp. Company Blog

The Aristocrat Group Corp. News:

ASCC Forms Vodka Distribution Strategy

ASCC Targets August Sales Debut for RWB Ultra-Premium Gluten-Free Vodka

ASCC Declares Market Conditions Ideal for Upcoming Vodka Launch

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.042, on 2,232,435 volume with 98 trades. The stock’s average daily volume over the past 60 days is 2,004,520, and its 52-week low/high is $0.0275/$0.155.

Advaxis Inc. announced submission today of an Orphan Drug Designation application with the FDA for their lead drug candidate, the HPV-associated head and neck cancer treatment known as ADXS-HPV. Given the epidemic rate of increase in this type of cancer, with some 500k new cases of head and neck cancer annually, ADXS is pushing to get real help to the affected here, where as many as half of all cases can be traced back to HPV infection. The Orphan Drug Designation will really speed up the timetable for ADXS, which currently has the drug in a Phase 1/2 study in the UK, with U.S. trials planned for later this year.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Requests Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer with ADXS-HPV

Advaxis Issues Letter Advising Stockholders to Vote FOR Proposals 2 and 3 of Proxy Statement

Advaxis Requests Orphan Drug Designation for Treatment of Cervical Cancer with ADXS-HPV

Rainbow Coral Corp. (RBCC)

The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.32, up 6.67%, on 67,382 volume with 24 trades. The stock’s average daily volume over the past 60 days is 317,850, and its 52-week low/high is $0.10/$3.60.

Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.

Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.

The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.

The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer

Rainbow Coral Corp. Company Blog

Rainbow Coral Corp. News:

RBCC Explores New Funding for Expansion

RBCC Poised To Gain Share Of $142 Billion Market

RBCC to Drive Growth Through Personalized Medicine

International Stem Cell Corp. (ISCO) Extends Market Reach in Asia through Strategic Distribution Agreements

International Stem Cell, a biotech company developing novel stem cell-based therapies and skin care products, reports that its operating subsidiary, Lifeline Skin Care, has entered into distribution agreements to market its stem cell skin care products in Thailand and Viet Nam beginning this summer.

Per the agreement, My Son IEI will distribute Lifeline products in Viet Nam. My Son distributes to hospitals, pharmacies, and other retail locations and is the only company licensed to develop and market therapeutic stem cell products in Viet Nam. In addition to distributing the skin care products, ISCO and My Son are discussing avenues through which to leverage ISCO’s patented parthenogenetic stem cell technology to develop new and innovative therapies for Vietnamese consumers.

Thai distributor Advanced Skincare Technologies will market Lifeline Skin Care to physicians, spas, hospitals, and pharmacies in Thailand. The president of Advanced Skincare Technologies has an established presence in the market, having founded the first company in Asia to apply stem cell therapy to commercially treat patients suffering from cardiomyopathy, and is now focused on offering cosmetic stem cell treatments.

The distribution agreement is complementary to Lifeline’s existing distribution relationship in China and support Lifeline’s goal to capitalize on opportunities in the Asian market.

“We’re excited to have such strong and reputable partners that can quickly leverage their experience and resources to our mutual advantage,” Simon Craw, PhD, executive vice president of ISCO stated in the press release. “Asia is poised for huge sales growth in cosmetics in the next five years. According to Euromonitor, sales of cosmetics and toiletries in the Asia Pacific region is expected to surge 26 percent, compared to only 3.5 percent in North America. We’re pleased to be on the forefront of stem cell skincare in Asia.”

For additional information, visit www.InternationalStemCell.com

The Aristocrat Group Corp. (ASCC) Outlines Vodka Distribution Strategy

Today before the opening bell, the Aristocrat Group announced that it will be handling the distribution of its two new vodka brands through the wholly owned subsidiary TOP Shelf Distributing. This move was made to maximize profit potential in the booming $21.3 billion U.S. spirits industry.

According to the press release, artisan alcohol distillery Distilled Resources will deliver both craft vodka brands to TOP Shelf for distribution this summer. The first to debut will be RWB Ultra-Premium Handcrafted Vodka, an all-American spirit with federal approval to advertise its gluten-free status right on the label.

It is anticipated that both vodka brands will hit store shelves in August. The company is working now to set up distribution deals across the country, beginning with the top spirits markets.

“We’re carefully calibrating our distribution strategy to give ourselves the best chance of success in the most crucial markets in the U.S.,” stated ASCC CEO Robert Federowicz. “We’ve made no secret of our big plans for growth, and a perfect launch of our first two products is going to be a step toward achieving them.”

Via TOP Shelf Distributing, the Aristocrat Group is currently working to expand its presence by seeking out distribution deals with outside distillers and brewers. The company hopes to announce new agreements soon.

For more information, visit www.aristocratgroup.com

Advaxis, Inc. (ADXS) Submits Request for Orphan Drug Designation

Today, Advaxis, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reported the submission of an application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated head and neck cancer. It is currently estimated that there are 50,000 new cases of head and neck cancer annually, with about 15,000 deaths.

Orphan Drug Designation is granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the United States. Orphan Drug Designation entitles the sponsor to clinical protocol assistance with the FDA, as well as federal grants, tax credits, and a seven-year market exclusivity period.

“HPV-associated head and neck cancer is growing at an epidemic rate in the United States and other regions throughout the world. According to the U.S. Centers for Disease Control and Prevention (CDC), over 80% of new cases occur in men, who are not typically part of HPV vaccination programs,” stated Dr. Robert Petit, Chief Scientific Officer of Advaxis. “Data from our Phase 2 study in recurrent cervical cancer show that ADXS-HPV is an active treatment in this HPV-associated cancer. We believe that ADXS-HPV immunotherapy will show similar activity in HPV-associated head and neck cancer, given the shared causality of the cancers. We have one ongoing Phase 1/2 study in HPV-positive head and neck cancer in the United Kingdom and plan to initiate another in the United States in 2013. We believe ADXS-HPV could become an important new non-cytotoxic treatment for patients with HPV-associated head and neck cancer.”

“If granted, Orphan Drug Designation (ODD) for our lead drug candidate, ADXS-HPV, could expedite our ability to help the over 10,000 Americans that the American Cancer Society estimates will be newly diagnosed with HPV-associated head and neck cancer in 2013. ODD would also provide seven years of market exclusivity for ADXS-HPV if it is approved by the FDA, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of the $1.9 million regulatory application filing fee,” added Thomas A. Moore, Chairman and CEO of Advaxis. “It is believed that the number of new HPV-caused head and neck cancers in the United States now approaches the number of new cervical cancer cases. This indication, with these incentives, if achieved, could substantially increase the potential value of the ADXS-HPV franchise.”

For more information, visit www.advaxis.com

VistaGen Therapeutics, Inc. (VSTA) Offers a Unique Form of Rehabilitation

It is said that the ultimate goal of social work is simple: to come up with a dependable and cost effective way to rehabilitate society’s unproductive members. It’s a noble goal and strangely similar to what VistaGen has already accomplished in the world of pharmaceuticals.

VistaGen is a stem cell technology company that has managed to develop a drug testing system unlike any other. Using their proprietary technology, the company has created liver and heart cell based bioassay systems that allow new drugs to be easily and accurately tested for heart and liver toxicity right in the laboratory, well before going through the time and expense of complex clinical trials.

It’s a highly cost-effective system that re-opens the door to previously developed drugs that have had to be shelved due to toxicity issues. By using this new efficient testing system, called Human Clinical Trials in a Test Tube, drugs can be tested and, if necessary, modified without breaking the bank. It’s an approach that could save the drug industry billions of dollars in wasted expenditures, representing significant revenue potential for VistaGen.

But the new test technology could also allow VistaGen itself to generate a diverse drug pipeline, consisting of new, proprietary, small molecule variants of once-promising drug candidates. This is the company’s stated strategy, and essentially represents the rehabilitation of shelved and unproductive drugs.

Together with a medicinal chemistry collaborator, VistaGen is planning to design and generate a portfolio of drug rescue variants of such discontinued drug candidates. They will then develop variants with equal or improved efficacy but with reduced toxicity or metabolism issues. In effect, they will be taking good advantage of the work already done by pharmaceutical companies, by putting the last pieces in place to allow the once unproductive drug to realize its full potential, an example of rehabilitation at its best.

For additional information, visit www.VistaGen.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Stock Analyzer




FOX Penny Stocks

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251